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Chagas  disease,  caused  by  the  protozoan  Trypanosoma  cruzi,  is  an  endemic  illness  in Latin  America.  Efforts
have  been  made  by  several  groups  to  develop  new  effective  and  safe  anti-T.  cruzi  drugs.  In  the present
work,  we  show  that  thiazolidine  LPSF  SF29  inhibited  growth  of the  epimastigote  and  amastigote  formseywords:
lectron microscopy
rypanosoma cruzi
hemotherapy
hiazolidines
itochondria
and  caused  lysis  in  the trypomastigote  form  of  T.  cruzi,  leading  to  death  of  the  protozoan.  Mitochondrial
dysfunction  was  also  observed.  The  thiazolidine  induced  ultrastructural  alterations  such  as  detachment  of
the  ﬂagellar  membrane,  intense  mitochondrial  swelling,  formation  of  myelin-like  ﬁgures  and  the  appear-
ance  of autophagosomes.  Taken  together,  these  results  suggest  that  this  new  thiazolidine  is  active  against
T.  cruzi  and  constitutes  a promising  drug  for the  therapy  of  Chagas  disease.
© 2012 Elsevier B.V. and the International Society of Chemotherapy. Open access under the Elsevier OA license. . Introduction
Species from the Trypanosomatidae family are responsible for
iseases known as neglected diseases, which are of great medical
mportance. Among these, Chagas disease is an endemic illness in
atin America caused by the protozoan Trypanosoma cruzi. The main
rugs used for the treatment of Chagas disease are benznidazole
LAFEPE) and nifurtimox (Lampit®; Bayer), which present signiﬁ-
ant side effects and cure <20% of patients during chronic Chagas
isease [1]. Thus, many researchers have combined efforts to dis-
over drugs against new targets looking for lower toxicity and a
reater tolerance by patients, aiming not only for efﬁciency in the
cute phase but also in the chronic phase.
Here we investigated a class of compounds that has been little
xplored for Chagas disease chemotherapy, the thiazolidines. These
ompounds are isosteric imidazolidines with a ﬁve-membered het-
rocyclic ring, with nitrogen and sulphur as the heteroatoms in
ositions 1 and 3 of the ring; they have similar properties to imi-
azolidines, which inhibited epimastigote growth. Imidazolidines
an interfere with polyamine biosynthesis in the parasite, and
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Open accesspolyamines are used in trypanothione synthesis [2]. Trypanothione,
a parasite molecule involved in protozoan protection against oxida-
tive stress, is now considered a virulence factor of Chagas disease
[3]. Thus, the use of molecules that interfere with trypanoth-
ione biosynthesis may  lead to parasite death. These thiazolidines
have the ability to function against various biological targets and
have attracted the interest of several research groups. An exam-
ple is l-thiazolidine-4-carboxylic acid, an analogue of l-proline
that showed signiﬁcant effects on T. cruzi epimastigote l-proline
metabolism and life cycle. The drug also showed activity against
trypomastigotes at concentrations that are non-toxic to mam-
malian cells [4]. This ﬁnding suggests that the thiazolidine family
of drugs could be used as potential chemotherapeutic agents.
The  present work analysed the effects of 5-(3,4-dichloro-
benzylidene)-3-(4-nitrobenzyl)-thiazolidine-2,4-dione (LPSF
SF29) on the growth and structural organisation of the epi-
mastigote, amastigote and trypomastigote forms of T. cruzi. Flow
cytometry and ﬂuorescence, scanning and transmission elec-
tron microscopy were used for this in-depth analysis. The results
showed that this compound inhibits, at low micromolar concentra-
tions, the growth of the proliferative epimastigote and amastigote
forms and induces lysis in the trypomastigote form. Parasite death
is due to signiﬁcant alterations in the plasma membrane and
mitochondrion, with the appearance of autophagosomes.
    under the Elsevier OA license. 
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. Materials and methods
.1.  Parasite and cell culture
Epimastigotes  of T. cruzi Y (TcII) were grown in liver infusion
ryptose (LIT) medium [5] supplemented with 10% fetal bovine
erum (FBS) (Gibco, Grand Island, NY) at 28 ◦C. Trypomastigotes
ere obtained from the supernatant of LLC-MK2 cells 7 days post
nfection. For experiments with amastigotes, resident peritoneal
acrophages were obtained from Swiss mice, according to the
ecommendations of the Ethics Committee of Carlos Chagas Filho
iophysics Institute, permit no. 106). Macrophages were plated in
 24-well plate or on Petri plates, infected with trypomastigotes in
 ratio of 10 parasites:1 cell for 2 h, washed and further incubated
or 24 h. LLC-MK2 cells and macrophages were cultivated in RPMI
edium (Gibco) supplemented with 10% FBS at 37 ◦C in a 5% CO2
tmosphere.
.2. Chemical synthesis
5-  (3,4-Dichloro-benzylidene) -3-(4-nitrobenzyl) -thiazolidine-
,4-dione (LPSF SF29) was synthesised by the research group of the
rug Design Laboratory at the Federal University of Pernambuco
Recife, Brazil). The starting reagent was thiazolidine-2,4-dione,
hich reacted with a benzyl halide under basic conditions to
btain the 3-(4-nitrobenzyl)-thiazolidine-2,4-dione intermediate.
aterally, 3-(3,4-dichloro-phenyl)-2-cyano-2-propenoic acid ethyl
ster (LPSF IP17) was synthesised by Knoevenagel condensation
etween 3,4-dichloro-benzaldehyde and ethyl cyanoacetate. As
 ﬁnal step, a Michael-type addition was performed by reacting
he N-benzyl intermediate with LPSF IP17 in the presence of
iperidine, forming the ﬁnal thiazolidine LPSF SF29.
Previously published chemical data for the 3-(4-nitrobenzyl)-
hiazolidine-2,4-dione intermediate [6,7] are not reported here.
.3. Analysis of the effects of LPSF SF29 on the epimastigote,
rypomastigote and amastigote forms of Trypanosoma cruzi
Epimastigotes (2 × 106 cells/mL) in the exponential growth
hase were seeded in LIT medium supplemented with 10% FBS at
8 ◦C. After 24 h, LPSF SF29 was added at different concentrations
nd parasite growth was monitored daily until 72 h of treatment.
wo control groups were performed: medium alone and medium
ith 0.25% dimethyl sulphoxide (DMSO). Quantiﬁcation of para-
ites was performed in a Neubauer chamber to estimate the 50%
nhibitory concentration (IC50). Trypomastigotes obtained from the
upernatant of LLC-MK2 cells were centrifuged (2000 × g, 30 min),
e-suspended (106 cells/mL) in RPMI medium with 5% FBS and
reated with LPSF SF29 at different concentrations (7–20 M)  for
4 h at 37 ◦C. Parasites treated with DMSO (0.3%) were used as
ontrols. After 24 h of treatment, live parasites were counted in a
eubauer chamber.
To  analyse the activity of LPSF SF29 on intracellular amastig-
tes, the assay was carried out as described previously [8]. Infected
eritoneal macrophages were treated with LPSF SF29 at different
oncentrations (0.75–8.0 M)  and maintained for 96 h. Cover-
lips were processed and assay analyses were also performed as
escribed previously [8]. Parasite infection was quantiﬁed under a
eiss Axioplan light microscope (Carl Zeiss AG, Jena, Germany).
All  drug activities were calculated using SigmaPlot® v.10 (Sys-
at Software Inc., San José, CA). To compare control and treated
roups among all assays, paired t-tests were applied to results using
 95% conﬁdence interval (GraphPad Prism v.5.00 for Windows;
raphPad Software Inc., San Diego, CA). Antimicrobial Agents 41 (2013) 183– 187
2.4.  Viability tests with the tetrazolium salt MTS
The 3-(4,5-dimethyl-2-thiazolyl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner
salt/5-methylphenazinium methyl sulphate (MTS/PMS) assay was
performed in epimastigotes as described previously [9]. Untreated
epimastigotes as well as epimastigotes treated with LPSF SF29
for 72 h were centrifuged at 2000 × g for 5 min  to remove the
LIT medium. The 96-well plate was incubated at 28 ◦C for 2–4 h
and was read at 490 nm in a SpectraMax M2 Microplate Reader
(Molecular Devices, Sunnyvale, CA).
2.5. Flow cytometry and ﬂuorescence microscopy
Epimastigotes treated or not with 12 M of LPSF SF29 for 72 h
were incubated for 20 min  with 2 g/mL rhodamine 123 (Sigma
Chemical Co., St Louis, MO)  and 10 g/mL ethidium bromide (EB)
(Molecular Probes, Carlsbad, CA). Epimastigotes were diluted in
saline buffer containing glucose (SBG) to 4 × 106 parasites/mL and
were analysed using a FACSCalibur Flow Cytometer (BD, Franklin
Lakes, NJ). Data analysis was carried out using Summit v.4.3 (Sum-
mit Software Solutions Inc., Poway, CA).
For analysis of the mitochondrial membrane potential by ﬂu-
orescence microscopy, epimastigotes were treated or not with
12 M LPSF SF29 for 72 h, washed in SBG and incubated with
5 g/mL rhodamine 123 (Sigma Chemical Co.) for 20 min  at 28 ◦C,
washed three times in phosphate-buffered saline and analysed
under a Zeiss Axioplan ﬂuorescence microscope (Carl Zeiss AG).
2.6. Morphological analysis using scanning electron microscopy
(SEM)  and transmission electron microscopy (TEM)
Control epimastigotes and epimastigotes treated with LPSF SF29
at the IC50 were ﬁxed with 2.5% grade II glutaraldehyde in 0.1 M
cacodylate buffer (pH 7.2), washed in the same buffer and processed
as described previously [8]. Samples were ion-sputtered with a 20-
nm gold layer and observed in a Zeiss DSM 962 scanning electron
microscope (Carl Zeiss, Oberkochen, Germany).
Control and LPSF SF29-treated epimastigotes, trypomastigotes
and intracellular amastigotes were ﬁxed, post-ﬁxed and processed
as previously described [8]. Ultrathin sections were stained with
uranyl acetate and lead citrate and observed in a JEOL JEM-1200EX
transmission electron microscope (JEOL, Tokyo, Japan) operating at
80 kV.
3.  Results and discussion
Chagas  disease therapy (nifurtimox and benznidazole) has been
used since the 1970s and presents severe side effects with long
treatment, often leading to discontinuation of therapy. Therefore,
continuous efforts have been made to discover new drugs, mainly
for the chronic phase. Owing to their potential antiparasitic activ-
ity against several pathogens, the thiazolidine compounds have
attracted enormous interest within the scientiﬁc community [2,3].
In this study, we showed the effects against T. cruzi of a new
compound, the thiazolidine LPSF SF29 (C17H10Cl2N2O4S) (Supple-
mentary Fig. S1). Treatment of T. cruzi epimastigotes with 5–12 M
of LPSF SF29 showed a dose- and time-dependent effect on para-
site growth, with an IC50 of 8.7 ± 0.83 M after 72 h of treatment
(Table 1), a lower value than the IC50 of the reference drug ben-
znidazole (10.4 M)  [10]. The epimastigote IC90 (90% inhibitory
concentration) was calculated as >12 M.  This trypanocidal effect
was conﬁrmed by the MTS  colorimetric method.
Supplementary Fig. S1 associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.ijantimicag.
2012.09.018.
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Table  1
Trypanocidal activities of LPSF SF29 on epimastigote, trypomastigote and intracellular amastigote forms of Trypanosoma cruzi Y (TcII).
IC50 (M) IC90 (M) LC50 (M) LC90 (M)
Epimastigotes Amastigotes Epimastigotes Amastigotes Trypomastigotes
0 
I entrat
d
t
l
c
(
o
L
f
t
(
(
t
t
a
t
a
m
F
p
a
cLPSF SF29 8.7 ± 0.83 4.5 ± 1.3 >12.
C50/90, 50% and 90% inhibitory concentration, respectively; LC50/90, compound conc
These experiments also provide clear evidence that LPSF SF29
isplays a trypanocidal effect against trypomastigotes, the infec-
ive form of T. cruzi, and shows a progressive increase in parasite
ysis, with an LC50 value (compound concentration that reduces
ellular viability by 50%) of 14.3 ± 2.10 M and an LC90 value
compound concentration that reduces cellular viability by 90%)
f >20 M (Table 1). In addition, the IC50 and IC90 values of
PSF SF29 against the amastigote form, the clinically important
orm of T. cruzi, were also quantiﬁed. The compound inhibited
he growth of the intracellular amastigote at low concentrations
IC50 = 4.5 ± 1.3 M and IC90 = 17 ± 3.5 M)  after 96 h of treatment
Table 1). The IC50 value of the reference drug benznidazole against
he intracellular amastigote form was 2.6 ± 0.2 M after 72 h of
reatment. An important criterion in the search for compounds
ctive against intracellular parasites with therapeutic potential is
heir low toxicity to mammalian host cells. LPSF SF29 did not show
ny toxicity effects with concentrations up to 32 M on peritoneal
acrophages, as analysed using the Trypan blue method (data not
ig. 1. Flow cytometry analysis of parasites treated with 12 M LPSF SF29 for 72 h evaluat
otential of epimastigotes of Trypanosoma cruzi: (A and C) control parasites; and (B and D
nd  represents single- and double-positive parasites labelled with ethidium bromide (EB)
ontrol  and drug-treated groups, respectively. Black arrow indicates the population of pa17 ± 3.5 14.3 ± 2.10 >20.0
ion that reduces cellular viability by 50% and 90%, respectively.
shown). Furthermore, intracellular amastigotes are 7.1 times more
sensitive to the compound than macrophages. Thus, LPSF SF29
showed promising and selective parasite inhibition at micromolar
dosages without effects on peritoneal macrophages, demonstrat-
ing a good selective index against the parasite forms present in the
vertebrate host.
Analysis  by SEM revealed that treatment for 72 h with 12 M
LPSF SF29 caused rounding, twisting and a decrease in the cell
body length of epimastigotes, whilst the control group remained
with its typical morphology (Supplementary Fig. S2). These effects
suggest a possible association of drug action on the composition
of the plasma membrane and disorganisation of the cytoskele-
ton [11]. Analysis by TEM showed that epimastigotes treated with
7 M and 10 M LPSF SF29 for 72 h displayed ﬂagellar mem-
brane enlargement and detachment from the axoneme structure
of the ﬂagellar membrane. In addition, the drug also altered the
mitochondrion, with swelling and formation of concentric mem-
brane structures inside the organelle (Supplementary Fig. S3).
ing general morphology, plasma membrane integrity and mitochondrial membrane
) drug-treated parasites. The percentage of positive cells is shown in each quadrant
 and rhodamine 123. R1 and R3 represent the region of analysis for parasites in the
rasites with altered morphology induced by the treatment.
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Fig. 2. Transmission electron microscopy images of trypomastigotes and intracellular amastigotes of Trypanosoma cruzi treated with LPSF SF29. (A) Control trypomastigote
after 24 h of incubation showing normal nucleus (n), kinetoplast (k) and ﬂagellum (f). Bar, 0.1 m.  (B) Parasites treated with 20 M LPSF SF29 for 24 h, with large vacuole
near the ﬂagellum. Bar, 0.1 m.  (C) Untreated intracellular amastigote after 96 h of incubation showing normal morphology. k, kinetoplast; n, nucleus; f, ﬂagellum; a,
acidocalcisome. (D–H) LPSF SF29 treatment induced formation of autophagosomes (black arrowhead in D and black arrow in G), intense mitochondrial swelling (arrow in
E plasm
a ; D–F
T
b
l
m
l
m
m
s),  formation of membrane within the mitochondrion (white arrowhead in F), cyto
rrow  in F), and large vacuole in the cell cytoplasm (black arrow in H). Bars: C, 2 m
hese mitochondrial effects are similar to the alterations caused
y sterol biosynthesis inhibitors such as lysophospholipid ana-
ogues and posaconazole/amiodarone [7,12]. These drugs modulate
embrane permeability and ﬂuidity, the metabolism of phospho-ipids, and proliferation signal transduction [8,12]. These concentric
itochondrial membrane structures were also observed in pro-
astigotes of Leishmania amazonensis treated with an inhibitor of
terol biosynthesis [11]. The formation of myelin-like ﬁgures was vacuolisation (black star) and disruption of the parasite plasma membrane (black
, 0.5 m; G, 2 m;  H, 3 m.
also  observed. All these alterations can lead to programmed cell
death mechanism activation [13]. Flow cytometry assays using epi-
mastigote forms treated with 12 M for 72 h showed that this drug
induced alterations in parasite morphology (Fig. 1A, B, black arrow)
and a reduction in parasite viability. It was observed that <1% of the
parasites in the control group had a damaged plasma membrane
(EB+ parasites; Fig. 1C) but ca. 27% of the cells in the drug-treated
group showed no membrane integrity (Fig. 1D).Moreover, parasite
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[T.L. de B. Moreira et al. / International Jour
reatment led to a reduction of ca. 30% of parasites labelled with
hodamine 123 (Fig. 1D), conﬁrming the intense mitochondrial
amage. Observations using ﬂuorescence microscopy of epimastig-
tes labelled with rhodamine 123 of treated parasites also showed
 less intense labelling (data not shown). This was  previously
eported using other imidazolidines [2] and was also described after
reatment with reversed amidines [14]. These results, as well as the
hanges observed by TEM, together suggest the mitochondria as the
rimary target for this drug action.
Supplementary Figs. S2 and S3 associated with
his article can be found, in the online version, at
ttp://dx.doi.org/10.1016/j.ijantimicag.2012.09.018.
Ultrastructural analysis of trypomastigotes treated with 12 M
nd 20 M LPSF SF29 for 24 h revealed an enlargement of the ﬂa-
ellar pocket and the presence of a large vacuole in the cytoplasm
Fig. 2B) as well as mitochondrial swelling (data not shown). This
arge vacuole resembles the contractile vacuole observed in all
evelopmental forms of T. cruzi [15]. This large vacuole was not
bserved in untreated trypomastigotes, so we can speculate that
his alteration is probably due to the osmotic alteration caused by
he drug inside the trypomastigote form. This osmotic alteration
an cause trypomastigote lysis.
Macrophages previously infected for 24 h and containing intra-
ellular amastigote forms of T. cruzi were incubated with 4.5 M
PSF SF29 for 96 h and then processed for observation by TEM.
o alterations were visualised in untreated infected macrophages,
howing normal amastigotes. Treated infected macrophages
howed that the amastigotes presented vacuoles similar to
utophagosomes, intense mitochondrial swelling, membrane for-
ation inside the mitochondria, and cytoplasm vacuolisation
Fig. 2C–H). Cytoplasm vacuolisation was also observed in the
mastigote forms after treatment with elatol, a compound isolated
rom Laurencia dendroidea [10], and after treatment with reversed
midines [14].
We  conclude that the thiazolidine LPSF SF29 represents a new
rug to be further tested against T. cruzi since it causes try-
omastigote lysis and amastigote death, probably by interfering
ith polyamine biosynthesis and consequently with trypanothione
iosynthesis, which causes the parasites to became more sensitive
o oxidative metabolism.
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